Skip to Content


In the US, Idarucizumab (idarucizumab systemic) is a member of the drug class anticoagulant reversal agents and is used to treat Reversal of Dabigatran Anticoagulation.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Categories

Antidote: Anticoagulant antagonist


Chemical Name

Immunoglobulin Fab G1-kappa, anti-[dabigatran], humanized monoclonal antibody;VH-(CH1-hinge) gamma1 heavy chain (1-225) [humanized VH (Homo sapiensIGHV4-59*01 (82.30%) -(IGHD)-IGHJ4*01) [8.7.16] (1-122) -Homo sapiensIGHG1*01 (CH1 (123-220), hinge 1-5 (221 (WHO)

Foreign Names

  • Idarucizumabum (Latin)
  • Idarucizumab (German)
  • Idarucizumab (French)
  • Idarucizumab (Spanish)

Generic Names

  • Idarucizumab (OS: USAN, JAN)
  • UNII-97RWB5S1U6 (IS)

Brand Names

  • Praxbind
    Boehringer Ingelheim, France; Boehringer Ingelheim, United Kingdom; Boehringer Ingelheim International, Germany; Boehringer Ingelheim Pharmaceuticals, United States


ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.